Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹27.80, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 39x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹28.50, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 38x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years. New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (₹309.4m market cap, or US$3.26m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Board Change • Apr 06
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jan 29
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Nov 13
Walpar Nutritions Limited to Report First Half, 2026 Results on Nov 13, 2025 Walpar Nutritions Limited announced that they will report first half, 2026 results on Nov 13, 2025 Board Change • Nov 10
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Sep 04
Walpar Nutritions Limited, Annual General Meeting, Sep 25, 2025 Walpar Nutritions Limited, Annual General Meeting, Sep 25, 2025, at 12:00 Indian Standard Time. New Risk • May 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹438.7m market cap, or US$5.13m). Minor Risks High level of debt (46% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹52.30, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 66x in the Personal Products industry in India. Total returns to shareholders of 185% over the past three years. Duyuru • Jul 09
Walpar Nutritions Limited, Annual General Meeting, Jul 30, 2024 Walpar Nutritions Limited, Annual General Meeting, Jul 30, 2024, at 12:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹115, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 59x in the Personal Products industry in India. Total returns to shareholders of 51% over the past year. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹129, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 55x in the Personal Products industry in India. Total returns to shareholders of 57% over the past year. New Risk • May 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$10m (₹543.6m market cap, or US$6.54m). Minor Risks High level of debt (56% net debt to equity). Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). New Risk • May 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$10m (₹558.1m market cap, or US$6.68m). Minor Risk High level of debt (56% net debt to equity). Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹122, the stock trades at a trailing P/E ratio of 40.5x. Average trailing P/E is 53x in the Personal Products industry in India. Total returns to shareholders of 137% over the past year. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹116, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 55x in the Personal Products industry in India. Total returns to shareholders of 85% over the past year. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹94.70, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 61x in the Personal Products industry in India. Total returns to shareholders of 50% over the past year. Reported Earnings • Nov 11
First half 2024 earnings released First half 2024 results: EPS: ₹0.85. Net income: ₹3.97m (up ₹3.97m from 1H 2023). Reported Earnings • Oct 12
Full year 2023 earnings released: EPS: ₹1.30 (vs ₹0.90 in FY 2022) Full year 2023 results: EPS: ₹1.30 (up from ₹0.90 in FY 2022). Revenue: ₹353.6m (up 32% from FY 2022). Net income: ₹5.90m (up 55% from FY 2022). Profit margin: 1.7% (up from 1.4% in FY 2022). The increase in margin was driven by higher revenue. Duyuru • Sep 27
Walpar Nutritions Limited, Annual General Meeting, Sep 26, 2023 Walpar Nutritions Limited, Annual General Meeting, Sep 26, 2023, at 11:19 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended on 31 March 2023 and Statement of Profit and Loss together with the notes forming part thereof along with Cash Flow Statement for the financial year ended on that date, and the Reports of the Board of Directors (The Board) and the Auditors thereon; and to consider Board changes. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹86.35, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 50x in the Personal Products industry in India. Total returns to shareholders of 118% over the past year. Reported Earnings • May 24
Full year 2023 earnings released: EPS: ₹2.51 (vs ₹0.90 in FY 2022) Full year 2023 results: EPS: ₹2.51 (up from ₹0.90 in FY 2022). Revenue: ₹354.8m (up 33% from FY 2022). Net income: ₹5.90m (up 55% from FY 2022). Profit margin: 1.7% (up from 1.4% in FY 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹59.40, the stock trades at a trailing P/E ratio of 70.9x. Average trailing P/E is 51x in the Personal Products industry in India. Total returns to shareholders of 123% over the past year. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improved over the past week After last week's 16% share price gain to ₹61.25, the stock trades at a trailing P/E ratio of 73.1x. Average trailing P/E is 57x in the Personal Products industry in India. Total returns to shareholders of 101% over the past year. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improved over the past week After last week's 16% share price gain to ₹59.55, the stock trades at a trailing P/E ratio of 71x. Average trailing P/E is 63x in the Personal Products industry in India. Total returns to shareholders of 65% over the past year. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improved over the past week After last week's 16% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 46.6x. Average trailing P/E is 47x in the Personal Products industry in India. Total loss to shareholders of 12% over the past year. Recent Insider Transactions • Jul 18
Executive Director & CFO recently bought ₹2.4m worth of stock On the 14th of July, Sejal Ladhawala bought around 68k shares on-market at roughly ₹34.77 per share. This was the largest purchase by an insider in the last 3 months. This was Sejal's only on-market trade for the last 12 months. Duyuru • Feb 03
Walpar Nutritions Limited Announces Resignation of Mr. Parin Patel from the Post of Independent Director Walpar Nutritions Limited announced that company had submitted intimation of resignation of Mr. Parin Patel from the post of Independent Director of the Company on 11th January, 2022. Resignation is w.e.f. 11th January, 2022 due to his appointment as Business Development Manager in the Company. Executive Departure • Aug 28
Company Secretary & Compliance Officer Palakben Joshi has left the company On the 25th of August, Palakben Joshi's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Palakben's name. Palakben is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. 
